KEY FINDINGS
Propelled by factors like the low performance of branded drugs as compared to generic drugs and rising spending on healthcare and research, the global drug discovery market is expected to make a leap of 9.73% CAGR, increasing its revenue from $ 36.7 billion to $83.6 billion between the forecast years of 20182026.
MARKET INSIGHTS
Technologywise, the global drug discovery market is segmented into Protein Microarrays, QPCR, Mass Spectrometry, DNA Microarrays, High Throughput Screening, Protein and Nucleic Acid Isolation, Gel Electrophoresis, Chromatography, and Other Technologies. Extensive RD for new product launches can be viewed as major opportunities for the market to expand.
REGIONAL INSIGHTS
North America, AsiaPacific, Europe and Rest of World are the geographical segments of this market. By the end of the forecast period, the North American market is anticipated to account for the lion's share of the global market. The U.S is expected to be a major contributor to this region, driven by high healthcare spending and growing lifestyle oriented diseases. Also, the AsiaPacific market is predicted to register the fastest growth driven by high investments and growing RD.
COMPETITIVE INSIGHTS
Noted players in the global drug discovery market include Bayer Ag, AstraZeneca Plc, Boehringer Ingelheim, F. HoffmannLa Roche Ltd, Eli Lily, GlaxoSmithKline Llc, Merck Co. Inc, Sanofi and Pfizer Inc.
Original Article: GLOBAL DRUG DISCOVERY MARKET FORECAST 20182026 [Report Updated: 15012018] Prices from USD $2500
NEXT ARTICLE